Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis

Clin Infect Dis. 2021 Oct 5;73(7):e2338-e2341. doi: 10.1093/cid/ciaa1544.

Abstract

We investigated the value of susceptibility testing in predicting response in AIDS-associated cryptococcal meningitis using clinical isolates from a randomized controlled trial of antifungal treatment (amphotericin monotherapy, amphotericin with flucytosine, or amphotericin with fluconazole). We found no correlation between antifungal susceptibility and either early or late survival, or fungal clearance.

Keywords: HIV; cryptococcal meningitis; mortality; outcome; susceptibility testing.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome* / complications
  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Fluconazole / pharmacology
  • Fluconazole / therapeutic use
  • Flucytosine / therapeutic use
  • Humans
  • Meningitis, Cryptococcal* / drug therapy

Substances

  • Antifungal Agents
  • Fluconazole
  • Flucytosine